Home   About this service   Get the news  
+32 2 743 34 03

 Belgium  Other Countries
Page : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - ...
WAREHOUSE ESTATES BELGIUM S.C.A. [BE0003734481/WEB]   
[29/06/2018]

WAREHOUSE ESTATES BELGIUM S.C.A. : WEB SCA - RESULTATS SEMESTRIELS AU 31/03/2018

WAREHOUSES ESTATES BELGIUM S.C.A. “We are building opportunities“   Information réglementée ... See more
 
UCB [BE0003739530/UCB]   
[28/06/2018]

UCB : UCB Media Room: IFPA 2018 Data Release

New UCB Research Showcases Value of CIMZIA® certolizumab pegol in Psoriasis and Highlights Unique Experiences and Real World Evidence for Key Patient PopulationsCIMZIA, the only Fcfree, PEGylated antiTNF, recently received marketing authorization from the European Commission for the treatment of adults with moderate to severe plaque psoriasisBrussels, Belgium – 28 June 2018 – UCB, a global... See more
 
D'IETEREN [BE0974259880/DIE]   
[27/06/2018]

D'IETEREN : Repurchase of own shares in the context of the liquidity contract

PRESS RELEASE: REPURCHASE OF OWN SHARES IN THE CONTEXT OF THE LIQUIDITY CONTRACT REGULATED INFORMATION Wednesday 27 June 2018 – 6:00 pm CET Repurchase of own shares in the context of... See more
 
Gimv [BE0003699130/GIMB]   
[27/06/2018]

Gimv : Report of the Annual General Shareholders’ Meeting - Approval of a gross dividend of EUR 2.50 per share

Antwerp, 27 June 2018, 17h45 CET Report of the Annual General Shareholders’ Meeting Approval of a gross dividend of EUR 2.50 per share Today Gimv held its Annual General Meeting AGM. 38.62 % of the shares were represented 9 820 417 shares. The AGM approved the gross dividend coupon nr. 25 of EUR 2.50 per share EUR 1.75 net. Gimv realised a... See more
 
ONCOMETHYLOME SCNC [BE0003844611/MDXH]   
[27/06/2018]

ONCOMETHYLOME SCNC : MDxHealth (MDXH-BR): Prostate cancer test proves value in pre-biopsy screening

goetzpartners securities Limited MDxHealth MDXHBR: Prostate cancer test proves value in prebiopsy screening 27Jun2018 / 13:43 GMT/BST Free to access research and investor meetings in a postMiFID2 world. This research report is intended for use only by persons who qualify as professional investors or eligible counterparties institutional investors in the applicable jurisdiction, and not by any...